FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia
In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-05-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/12/5/332 |
| _version_ | 1797567736309612544 |
|---|---|
| author | Lauren L. Spiegel Jill L. Ostrem Ian O. Bledsoe |
| author_facet | Lauren L. Spiegel Jill L. Ostrem Ian O. Bledsoe |
| author_sort | Lauren L. Spiegel |
| collection | DOAJ |
| description | In 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area. |
| first_indexed | 2024-03-10T19:46:43Z |
| format | Article |
| id | doaj.art-7acedf26706642ceb5837a8f01ffb71a |
| institution | Directory Open Access Journal |
| issn | 2072-6651 |
| language | English |
| last_indexed | 2024-03-10T19:46:43Z |
| publishDate | 2020-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj.art-7acedf26706642ceb5837a8f01ffb71a2023-11-20T00:47:03ZengMDPI AGToxins2072-66512020-05-0112533210.3390/toxins12050332FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of DystoniaLauren L. Spiegel0Jill L. Ostrem1Ian O. Bledsoe2Movement Disorders and Neuromodulation Center, Department of Neurology, University of California, San Francisco, CA 94115, USAMovement Disorders and Neuromodulation Center, Department of Neurology, University of California, San Francisco, CA 94115, USAMovement Disorders and Neuromodulation Center, Department of Neurology, University of California, San Francisco, CA 94115, USAIn 2016, the American Academy of Neurology (AAN) published practice guidelines for botulinum toxin (BoNT) in the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. This article, focusing on dystonia, provides context for these guidelines through literature review. Studies that led to Food and Drug Administration (FDA) approval of each toxin for dystonia indications are reviewed, in addition to several studies highlighted by the AAN guidelines. The AAN guidelines for the use of BoNT in dystonia are compared with those of the European Federation of the Neurological Societies (EFNS), and common off-label uses for BoNT in dystonia are discussed. Toxins not currently FDA-approved for the treatment of dystonia are additionally reviewed. In the future, additional toxins may become FDA-approved for the treatment of dystonia given expanding research in this area.https://www.mdpi.com/2072-6651/12/5/332botulinum toxindystoniacervical dystoniablepharospasmFDA |
| spellingShingle | Lauren L. Spiegel Jill L. Ostrem Ian O. Bledsoe FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia Toxins botulinum toxin dystonia cervical dystonia blepharospasm FDA |
| title | FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia |
| title_full | FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia |
| title_fullStr | FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia |
| title_full_unstemmed | FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia |
| title_short | FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia |
| title_sort | fda approvals and consensus guidelines for botulinum toxins in the treatment of dystonia |
| topic | botulinum toxin dystonia cervical dystonia blepharospasm FDA |
| url | https://www.mdpi.com/2072-6651/12/5/332 |
| work_keys_str_mv | AT laurenlspiegel fdaapprovalsandconsensusguidelinesforbotulinumtoxinsinthetreatmentofdystonia AT jilllostrem fdaapprovalsandconsensusguidelinesforbotulinumtoxinsinthetreatmentofdystonia AT ianobledsoe fdaapprovalsandconsensusguidelinesforbotulinumtoxinsinthetreatmentofdystonia |